A recent STAT article offers the opinions of several experts on how much Gilead’s COVID-19 treatment, remdesivir, should cost.
While ReVision Therapeutics’ Paul Fehlner suggests the treatment should cost less than a movie ticket, Northwestern University’s Kellogg School of Management Department of Health Care Director Craig Garthwaite says “it’s impossible to overpay for a truly effective drug.”
“If, at the margin, we slightly overpay for the drug and that makes even one more company move one more set of scientists to think about the problem of Covid-19 and that leads to a better drug, you almost can’t put a price on that,” he tells STAT.
To read the full article on STAT, click here.
